evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

6 questions · 8 findings · 2 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 7 · 87.5%Low 0 · 0%Moderate 1 · 12.5%High 0 · 0%

Low molecular weight heparin vs vitamin K antagonist (VKA)

Symptomatic catheter‐related thrombosis (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters

It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes symptomatic catheter‐related thrombosis (up to 3 months) compared with vitamin K antagonist (VKA) (very low certainty).

1 finding from 1 review

Low molecular weight heparin vs no LMWH

Symptomatic catheter‐related thrombosis (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters

Low‐molecular‐weight heparin (LMWH) probably leads to lower symptomatic catheter‐related thrombosis (up to 3 months) compared with no LMWH (moderate certainty).

1 finding from 1 review

Low molecular weight heparin vs vitamin K antagonist (VKA)

Symptomatic catheter‐related thrombosis measured as asymptomatic catheter‐related thrombosis (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters

It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes symptomatic catheter‐related thrombosis measured as asymptomatic… compared with vitamin K antagonist (VKA) (very low certainty).

1 finding from 1 review

Low molecular weight heparin vs no LMWH

Symptomatic catheter‐related thrombosis measured as asymptomatic catheter‐related thrombosis (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters

It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes symptomatic catheter‐related thrombosis measured as asymptomatic… compared with no LMWH (very low certainty).

1 finding from 1 review

Aspirin vs low molecular weight heparin

Symptomatic DVT · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether aspirin (ASA) changes symptomatic deep vein thrombosis compared with low molecular weight heparin (LMWH) (very low certainty).

2 findings from 1 review

Vitamin K antagonists vs low molecular weight heparin

Symptomatic DVT · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether vitamin K antagonist (VKA) changes symptomatic deep vein thrombosis compared with low molecular weight heparin (LMWH) (very low certainty).

2 findings from 1 review